ABBV
AbbVie Inc.
Quarterly revenue, EPS, free cash flow, valuation, and Rule of 40 scores for AbbVie Inc..
Coverage
AbbVie Q2 2026: Skyrizi and Rinvoq Keep Compounding — Stock Falls on a Narrow EPS Miss
AbbVie beat revenue estimates as Skyrizi and Rinvoq grew over 24% each, but adjusted EPS missed by 6 cents and full-year guidance came down, sending shares down nearly 5%. We break down the immunology growth story against the near-term guidance drag.
AbbVie Posts Double Beat for Q4
Q4 EPS $2.71 vs $2.65 est, revenue $16.62B vs $16.42B est; FY26 EPS guidance $14.37-$14.57 vs $14.24 est, signaling robust earnings growth.
AbbVie All In on Obesity
AbbVie signals heavy obesity focus without explicit statement; expected to compete with Novo Nordisk, Merck, Bristol-Myers Squibb, emphasizing efficacy over oral vs. subcutaneous.
AbbVie at JPM is All In on Obesity
AbbVie expresses enthusiasm for phase 1-2 obesity assets; anticipates big showdown with competitors like Novo Nordisk, Merck, and Lilly in weeks, not months.
Biopharma Sentiment Just Snapped Higher
Biopharma sentiment surged with BPSI index jumping 78 to 90; aligns with public market price action and deal flow, expecting continued M&A and IPO activity into summer.
Earnings release dates
| Quarter | End date | Publication date | Release |
|---|---|---|---|
| 2026 Q2 | 2026-06-30 | 2026-07-30 | Details → |
| 2026 Q1 | 2026-03-31 | 2026-05-01 | Details → |
| 2025 Q4 | 2025-12-31 | 2026-02-04 | Details → |
| 2025 Q3 | 2025-09-30 | 2025-10-31 | Details → |
| 2025 Q2 | 2025-06-30 | 2025-07-31 | Details → |
| 2025 Q1 | 2025-03-31 | 2025-04-25 | Details → |
| 2024 Q4 | 2024-12-31 | 2025-01-31 | Details → |
| 2024 Q3 | 2024-09-30 | 2024-10-30 | Details → |
| 2024 Q2 | 2024-06-30 | 2024-07-25 | Details → |
| 2024 Q1 | 2024-03-31 | 2024-04-26 | Details → |
| 2023 Q4 | 2023-12-31 | 2024-02-02 | Details → |
| 2023 Q3 | 2023-09-30 | 2023-10-27 | Details → |
| 2023 Q2 | 2023-06-30 | 2023-07-27 | Details → |
| 2023 Q1 | 2023-03-31 | 2023-04-27 | Details → |
| 2022 Q4 | 2022-12-31 | 2023-02-09 | Details → |
| 2022 Q3 | 2022-09-30 | 2022-10-28 | Details → |
| 2022 Q2 | 2022-06-30 | 2022-07-29 | Details → |
| 2022 Q1 | 2022-03-31 | 2022-04-29 | Details → |
| 2021 Q4 | 2021-12-31 | 2022-02-02 | Details → |
| 2021 Q3 | 2021-09-30 | 2021-10-29 | Details → |
| 2021 Q2 | 2021-06-30 | 2021-07-30 | Details → |
| 2021 Q1 | 2021-03-31 | 2021-04-30 | Details → |
| 2020 Q4 | 2020-12-31 | 2021-02-03 | Details → |
| 2020 Q3 | 2020-09-30 | 2020-10-30 | Details → |
| 2020 Q2 | 2020-06-30 | 2020-07-31 | Details → |
| 2020 Q1 | 2020-03-31 | 2020-05-01 | Details → |
Company History
AbbVie was formed as a spin-off from Abbott Laboratories, focusing on research-based pharmaceuticals; became independent on January 1, 2013.
Acquired ImmuVen, a startup focused on biotherapeutics for cancer, infectious diseases, and autoimmune disorders.
Acquired oncology firm Pharmacyclics and its blood cancer treatment ibrutinib for $21 billion.
Acquired Allergan for $63 billion, with divestitures to gain regulatory approval, including brazikumab to AstraZeneca and Zenpep/Viokace to Nestlé.
Evaluated Kaletra (lopinavir/ritonavir) as a potential COVID-19 treatment, later found ineffective, and ceased patent enforcement in response to government pressure.
Acquired ImmunoGen for $10.1 billion to enter the ovarian cancer market with the drug Elahere.
Robert Michael replaced Richard Gonzalez as CEO, with Gonzalez becoming executive chairman.
Key Players
showing 6 of 18 · see all leadership & board
